- Report
- January 2024
- 200 Pages
Global
From €3999EUR$4,150USD£3,440GBP
- Report
- May 2024
- 363 Pages
From €5252EUR$5,450USD£4,517GBP
- Report
- June 2021
- 120 Pages
Global
From €2409EUR$2,500USD£2,072GBP
- Report
- April 2023
- 90 Pages
Global
From €4577EUR$4,750USD£3,937GBP
- Report
- April 2023
- 175 Pages
Global
€4620EUR$4,795USD£3,974GBP
- Report
- October 2021
- 103 Pages
United States
From €2650EUR$2,750USD£2,279GBP
€5300EUR$5,500USD£4,559GBP
- Report
- January 2021
- 128 Pages
Global
From €3469EUR$3,600USD£2,984GBP
- Report
- January 2021
- 68 Pages
Europe
From €1445EUR$1,500USD£1,243GBP
- Report
- January 2021
- 68 Pages
Middle East, Africa
From €1445EUR$1,500USD£1,243GBP
- Report
- January 2021
- 64 Pages
North America
From €1445EUR$1,500USD£1,243GBP
- Report
- January 2021
- 68 Pages
Asia Pacific
From €1445EUR$1,500USD£1,243GBP
- Report
- May 2023
- 84 Pages
Global
From €3500EUR$3,891USD£3,116GBP
- Book
- April 2024
- 400 Pages
- Book
- June 2016
- 360 Pages
Smallpox is a highly contagious and potentially fatal disease caused by the variola virus. It is one of the most feared diseases in the world, and has been used as a weapon of bioterrorism. As a result, the biodefense market has been focused on developing treatments and vaccines for smallpox.
The smallpox market is a subset of the biodefense market, and is focused on developing treatments and vaccines for smallpox. Companies in this market are researching and developing drugs, vaccines, and other treatments to prevent and treat smallpox. These treatments are designed to be effective against both naturally occurring and weaponized forms of the virus.
Some companies in the smallpox market include Emergent BioSolutions, Dynavax Technologies, and Bavarian Nordic. These companies are researching and developing treatments and vaccines for smallpox, and are working to make them available to the public. Show Less Read more
